Jpmorgan Chase & CO Cogent Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 59,108 shares of COGT stock, worth $701,611. This represents 0.0% of its overall portfolio holdings.
Number of Shares
59,108
Previous 86,604
31.75%
Holding current value
$701,611
Previous $581,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding COGT
# of Institutions
161Shares Held
114MCall Options Held
104KPut Options Held
163K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$124 Million0.24% of portfolio
-
Commodore Capital LP New York, NY9.74MShares$116 Million7.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.26MShares$110 Million6.08% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$86.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$82.7 Million8.79% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $781M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...